Advanced Medical Solutions Group (CHIX:AMSL) 3-Year RORE % : -19.86% (As of Dec. 2025)


CHIX:AMSL Advanced Medical Solutions Group PLC CHIX:AMSL
93 GF Score
Price £2.81
GF Value £3.71
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Advanced Medical Solutions Group 3-Year RORE %?

Advanced Medical Solutions Group CHIX:AMSL 93 3-Year RORE % is -19.86 as of Dec. 2025. GuruFocus rates CHIX:AMSL with a GF Score™ of 93/100 and a GF Value™ of £3.71 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 781 Medical Devices & Instruments companies, Advanced Medical Solutions Group ranks worse than 76.31% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Advanced Medical Solutions Group's 3-Year RORE % for the quarter that ended in Dec. 2025 was -19.86%.

The industry rank for Advanced Medical Solutions Group's 3-Year RORE % or its related term are showing as below:

CHIX:AMSl's 3-Year RORE % is ranked worse than
76.31% of 781 companies
in the Medical Devices & Instruments industry
Industry Median: -4.27 vs CHIX:AMSl: -19.86

Advanced Medical Solutions Group  (CHIX:AMSl) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Advanced Medical Solutions Group 3-Year RORE % Related Terms


Advanced Medical Solutions Group 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Advanced Medical Solutions Group's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Medical Solutions Group 3-Year RORE % Chart

Advanced Medical Solutions Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.85 24.88 -2.85 -30.81 -19.86

Advanced Medical Solutions Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.85 -14.29 -30.81 -26.92 -19.86

CHIX:AMSL vs ISRG, BDX, MDLN: 3-Year RORE % Comparison

For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Medical Solutions Group 3-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Advanced Medical Solutions Group's 3-Year RORE % falls into.


CHIX:AMSL
93GF Score
Advanced Medical Solutions Group PLC CHIX:AMSL
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advanced Medical Solutions Group 3-Year RORE % Calculation

Advanced Medical Solutions Group's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.045-0.073 )/( 0.15-0.009 )
=-0.028/0.141
=-19.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -19.86 mean?
Advanced Medical Solutions Group (CHIX:AMSL) has a 3-Year RORE % of -19.86 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Advanced Medical Solutions Group and its competitors. According to the industry distribution chart, Advanced Medical Solutions Group ranks #596 out of 781 companies in the Medical Devices & Instruments industry, placing it in the top 76.3%.
Is Advanced Medical Solutions Group's 3-Year RORE % too high?
Advanced Medical Solutions Group's current 3-Year RORE % is -19.86. Based on the distribution chart, Advanced Medical Solutions Group ranks #596 out of 781 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Advanced Medical Solutions Group has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's 3-Year RORE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #596 out of 781 companies for 3-Year RORE %. This places Advanced Medical Solutions Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Advanced Medical Solutions Group and its competitors. Advanced Medical Solutions Group's current 3-Year RORE % is -19.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (CHIX:AMSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.71, compared to a current price of £2.81 — trading 24.4% below its estimated fair value. The current 3-Year RORE % is -19.86. Advanced Medical Solutions Group's overall GF Score™ is 93/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Advanced Medical Solutions Group (CHIX:AMSL), the current 3-Year RORE % is -19.86 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?

Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued. The current stock price of £2.81 is trading 24.4% below its estimated GF Value™ of £3.71. GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.

Key valuation signals for CHIX:AMSL:

  • 3-Year RORE %: -19.86
  • GF Value™: £3.71 vs. price of £2.81 (24.4% below fair value)
  • GF Score™: 93/100 with 8 warning signs

No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Advanced Medical Solutions Group Business Description

Other Exchanges AMS:UKAQA:Germany
Address Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire, GBR, CW7 3RT
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
93GF Score

Get the complete analysis for CHIX:AMSL

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£2.81
Price
£3.71
GF Value